Latest news

• EU concludes discussions with Moderna for COVID-19 vaccine

  Earlier this month, Moderna reached an agreement with the US government for an initial 100 million doses of its vaccine candidate mRNA-1273 in a deal worth up to $1.525bn. ... We are advancing the clinical development of mRNA-1273 with the ongoing phase

• US pays $1.5bn for 100 million doses of Moderna’s COVID-19 vaccine

  The candidate, mRNA-1273, reached clinical testing stage in record time, taking only 63 days after Moderna received the genetic code of the virus. ... We are advancing the clinical development of mRNA-1273 with the ongoing phase 3 study being conducted

• Moderna’s COVID-19 vaccine enters pivotal phase 3 trial

  The trial will investigate two shots of the candidate, mRNA-1273, at a dosage of 100 µg. ... Interim analysis from the phase 1 study of mRNA-1273 were published earlier this month, and showed that the vaccine produced rapid and strong immune responses

• Moderna’s COVID-19 vaccine produces immune response in early trial

  The initial results from participants who received both doses showed mRNA-1273 produced rapid and strong immune responses against SARS-CoV-2, the virus which causes COVID-19. ... We look forward to beginning our phase 3 study of mRNA-1273 this month to

• Moderna clashes with US scientists over pivotal COVID-19 vaccine trials

  Moderna released the first batch of its COVID-19 vaccine, mRNA-1273, for human use in February, with the initial doses sent to the US National Institute of Allergy and Infectious